Altogether, these results contribute to firmly establishing the interplay between FOXO3, autophagy and sorafenib resistance in this cancer type, supporting this new molecular mechanism that accounts for chemoresistance and opening a new therapeutic window to achieve better HCC patient outcomes. Here, FOXO3 is linked to hepatocellular carcinoma.